• GeneDx flagged new evidence supporting genomic newborn screening, with study updates set for presentation at ICoNS on Oct. 7-8 in Boston.
• GUARDIAN study results indicated strong enrollment, consistent performance across diverse ancestries, meaningful clinical findings, alongside existing newborn screening.
• Screening also surfaced actionable inherited cardiac-risk cases, prompting preventive treatment in infants, with follow-on testing identifying at-risk relatives.
• BRIDGES-NBS, a nationwide NIH-funded initiative, is scheduled to start enrolling this month to test multi-state rollout inside public screening programs.
• Program design targets early-life treatable conditions, positioning GeneDx to support broader clinical adoption if feasibility and outcomes hold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007662968) on October 07, 2026, and is solely responsible for the information contained therein.